Relapses in patients with giant-cell arteritis: prevalence, characteristics and associated clinical findings in a longitudinally followed cohort of 106 patients.

dc.contributor.authorAlba, Marco A.
dc.contributor.authorGarcía Martínez, Ana
dc.contributor.authorPrieto González, Sergio
dc.contributor.authorTavera Bahillo, Itziar
dc.contributor.authorCorbera Bellalta, Marc
dc.contributor.authorPlanas Rigol, Ester
dc.contributor.authorEspígol Frigolé, Georgina
dc.contributor.authorHernández Rodríguez, José
dc.contributor.authorCid Xutglà, M. Cinta
dc.date.accessioned2017-12-07T18:00:08Z
dc.date.available2017-12-07T18:00:08Z
dc.date.issued2014-07
dc.date.updated2017-12-07T18:00:08Z
dc.description.abstractGiant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p  < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec651032
dc.identifier.issn0025-7974
dc.identifier.pmid25181312
dc.identifier.urihttps://hdl.handle.net/2445/118572
dc.language.isoeng
dc.publisherLippincott, Williams & Wilkins. Wolters Kluwer Health
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1097/MD.0000000000000033
dc.relation.ispartofMedicine, 2014, vol. 93, p. 194-201
dc.relation.urihttps://doi.org/10.1097/MD.0000000000000033
dc.rightscc-by (c) Alba, Marco A. et al., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationArteritis de cèl·lules gegants
dc.subject.classificationEstadística mèdica
dc.subject.otherGiant cell arteritis
dc.subject.otherMedical statistics
dc.titleRelapses in patients with giant-cell arteritis: prevalence, characteristics and associated clinical findings in a longitudinally followed cohort of 106 patients.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
651032.pdf
Mida:
278.15 KB
Format:
Adobe Portable Document Format